SETDB1 and neoplasm: In Non-Small Cell Lung Cancers (NSCLC), upregulated SETDB1 expression favors tumor progression through interaction and methylation of p53 and Akt (AKT Serine/Threonine Kinase 1) [68,69,70], resulting in poorer prognosis and tumor recurrence in patients with stage I NSCLC [71,72].